CSBio CSBio

X
[{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Vaccine","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios Farmaceuticos Rovi"},{"orgOrder":0,"company":"Exeltis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Promotional Agreement with Exeltis on SOLOSEC\u00ae (secnidazole) Expanding Access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Exeltis"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HIPRA's Vaccine Against COVID-19, BIMERVAX\u00ae, Receives EMA's Positive Opinion","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Vaccine","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios HIPRA"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX\u00ae COVID-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SPAIN","productType":"Vaccine","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios HIPRA"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.

            Lead Product(s): Recombinant Protein Covid-19 Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Veristat

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 25, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Bimervax is a recombinant protein vaccine whose active substance is SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains, it provides immune response at humoral and cellular level, against the COVID-19.

            Lead Product(s): Recombinant Protein Covid-19 Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Bimervax

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 30, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This new agreement, which has a term of ten years, includes a series of investments expected to allow the manufacturing capacity of products including Spikevax, to increase across ROVI's facilities in Madrid, Spain.

            Lead Product(s): Elasomeran

            Therapeutic Area: Infections and Infectious Diseases Product Name: Spikevax

            Highest Development Status: Approved Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration February 16, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis.

            Lead Product(s): Secnidazole

            Therapeutic Area: Infections and Infectious Diseases Product Name: Solosec

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lupin Ltd

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement January 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY